V. Svicher

发表

The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing

F. Ceccherini‐Silberstein, G. Ippolito, M. Capobianchi, 2013, PloS one.

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

A. d’Arminio Monforte, F. Baldanti, F. Ceccherini‐Silberstein, 2012, The new microbiologica.

Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage

Stefano Alcaro, Giorgio Palù, Anna Artese, 2011, Antiviral therapy.

Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.

F. Baldanti, F. Ceccherini‐Silberstein, R. Maserati, 2010, The new microbiologica.

Inhibition of Dual/Mixed Tropic HIV-1 Isolates by CCR5-Inhibitors in Primary Lymphocytes and Macrophages

F. Ceccherini‐Silberstein, M. Andreoni, S. Aquaro, 2013, PloS one.

Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine

V. Calvez, F. Ceccherini‐Silberstein, B. Masquelier, 2011, ChemMedChem.

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype

B. Clotet, S. Marfil, J. Blanco, 2012, Retrovirology.

Incomplete APOBEC 3 G / F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR 5 to CXCR 4 Usage

V. Calvez, F. Ceccherini‐Silberstein, C. Perno, 2015 .

Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage

V. Calvez, F. Ceccherini‐Silberstein, C. Perno, 2015, Antimicrobial Agents and Chemotherapy.

Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment.

F. Ceccherini‐Silberstein, M. Andreoni, M. Ciotti, 2021, Methods.

HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation

F. Ceccherini‐Silberstein, S. Grelli, M. Andreoni, 2021, Biomedicines.

A snapshot of virological presentation and outcome of immunosuppression‐driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection

F. Ceccherini‐Silberstein, C. Delaugerre, M. Andreoni, 2019, Journal of viral hepatitis.

Establishment of a seronegative occult infection with an active HBV reservoir enriched of vaccine escape mutations in a vaccinated infant after liver transplant.

D. Liccardo, M. Ciotti, P. Francalanci, 2019, The Journal of infectious diseases.

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

M. Poljak, A. Wensing, R. Kaiser, 2016, The Journal of infectious diseases.

Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.

B. Berkhout, F. Ceccherini‐Silberstein, M. Andreoni, 2013, The Journal of infection.

Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis

F. Ceccherini‐Silberstein, E. Teti, M. Andreoni, 2020, Life.

Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages

M. Pellegrino, S. Aquaro, V. Svicher, 2020, Virulence.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

M. Poljak, A. Wensing, R. Kaiser, 2018, BMC Infectious Diseases.

Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2008, The Journal of infectious diseases.

Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection

M. Pellegrino, S. Aquaro, V. Svicher, 2021, Microorganisms.

Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen–positive liver transplant recipients after longterm minimal immunosuppression

G. Tisone, T. Manzia, L. Baiocchi, 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts

V. Svicher, L. Sarmati, V. Malagnino, 2019, Viruses.

A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART

V. Calvez, F. Ceccherini‐Silberstein, A. Antinori, 2014, PloS one.

Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs

F. Ceccherini‐Silberstein, M. Ciccozzi, C. Perno, 2009, BMC infectious diseases.

Dynamics of NRTI resistance mutations during therapy interruption.

Thomas Lengauer, F. Ceccherini‐Silberstein, P. Narciso, 2009, AIDS research and human retroviruses.

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.

F. Ceccherini‐Silberstein, B. Clotet, J. Martinez-Picado, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy

M. De Luca, B. Rizzuti, A. Garofalo, 2019, Molecules.

Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy.

M. Andreoni, C. Perno, A. Bertoli, 2012, The Journal of infection.

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis

M. Altieri, V. Vullo, C. Mastroianni, 2018, Open forum infectious diseases.

Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations

F. Ceccherini‐Silberstein, C. Perno, V. Svicher, 2011, Intervirology.

, Virus Type 1 Regulatory Protein Rev Mutations in the Human Immunodeficiency Enfuvirtide Influences the Appearance of Treatment with the Fusion Inhibitor

A. Laganà, F. Ceccherini‐Silberstein, A. Ferro, 2009 .

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.

V. Calvez, F. Ceccherini‐Silberstein, C. Katlama, 2010, The Journal of antimicrobial chemotherapy.

Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

E. Teti, M. Andreoni, V. Svicher, 2019, Journal of Medical Case Reports.

Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure

V. Svicher, U. Gill, P. Kennedy, 2022, Frontiers in Microbiology.

E. Teti, M. Andreoni, L. Coppola, 2022, Open forum infectious diseases.

48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.

A. Lazzarin, M. Clementi, L. Galli, 2016, The new microbiologica.

First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?

F. Ceccherini‐Silberstein, S. Grelli, P. Rogliani, 2022, Microorganisms.

Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis

V. Svicher, L. Piermatteo, R. Salpini, 2022, Journal of viral hepatitis.

Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers

F. Ceccherini‐Silberstein, E. Teti, M. Andreoni, 2020, Microorganisms.

Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B.

E. Sagnelli, C. Sagnelli, C. Perno, 2016, The Journal of infectious diseases.

Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.

Domenico Di Carlo, C. Perno, M. Andreoni, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.

R. Bruno, G. Antonelli, C. Perno, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach

F. Ceccherini‐Silberstein, E. Tramontano, S. Alcaro, 2022, Molecules.

Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages

R. Bruno, A. Modesti, S. Aquaro, 2017, Viruses.

C. Perno, V. Svicher, C. Alteri, 2011 .

Reliable timescale inference of HBV genotype A origin and phylodynamics.

M. Ciccozzi, E. Tanzi, M. Giovanetti, 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.

C. Perno, C. Perno, A. Bertoli, 2011, Antiviral research.

Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008.

M. Salemi, M. Ciccozzi, A. Lo Presti, 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.

V. Calvez, F. Ceccherini‐Silberstein, C. Perno, 2014, The Journal of antimicrobial chemotherapy.

Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Y. Louzoun, M. Andreoni, C. Perno, 2015, Hepatology.

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses

F. Ceccherini‐Silberstein, Y. Assaraf, S. Alcaro, 2020, Drug Resistance Updates.

Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.

F. Ceccherini‐Silberstein, C. Perno, S. Alcaro, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Mechanisms underlying activity of antiretroviral drugs in HIV‐1‐infected macrophages: new therapeutic strategies

A. Antinori, J. Balzarini, D. Schols, 2006, Journal of leukocyte biology.

Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model

Yang Liu, Valentina Svicher, C. Perno, 2013 .

Novel drug resistance mutations in HIV: recognition and clinical relevance.

Valentina Svicher, Francesca Ceccherini-Silberstein, F. Ceccherini‐Silberstein, 2006, AIDS reviews.

Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.

F. Ceccherini‐Silberstein, H. Fleury, F. Mazzotta, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.

F. Ceccherini‐Silberstein, C. Perno, A. Spanò, 2009, Journal of hepatology.

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro

F. Ceccherini‐Silberstein, C. Delaugerre, M. Levrero, 2020, Viruses.

Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal

V. Svicher, G. Maffongelli, L. Sarmati, 2017, BMC Infectious Diseases.

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.

F. Ceccherini‐Silberstein, A. Ursitti, C. Perno, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors

Stefano Alcaro, Anna Artese, Lucia Parrotta, 2012, PloS one.

Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution.

Valentina Svicher, Jens Verheyen, Valeria Micheli, 2013, The Journal of general virology.

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B

C. Perno, A. Nuccitelli, V. Svicher, 2020, Gut.

Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart

F. Ceccherini‐Silberstein, P. Narciso, E. Nicastri, 2013, Antiviral therapy.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro

Domenico Di Carlo, F. Ceccherini‐Silberstein, H. Fleury, 2017, Oncotarget.

Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0

M. Ciotti, F. Stazi, C. Perno, 2017, Medical Microbiology and Immunology.

Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.

B. Berkhout, H. Fleury, M. Andreoni, 2015, The Journal of infection.

Snapshot on drug‐resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

C. Perno, M. Andreoni, M. Angelico, 2013, Journal of medical virology.

An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression

F. Ceccherini‐Silberstein, Y. Oda, C. Perno, 2021, Microorganisms.

Therapeutic strategies towards HIV-1 infection in macrophages.

J. Balzarini, D. Schols, S. Aquaro, 2006, Antiviral research.

High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance

M. Andreoni, C. Perno, V. Svicher, 2018, PloS one.

Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.

Valentina Svicher, Jens Verheyen, Valeria Micheli, 2012, Antiviral research.

The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.

F. Ceccherini‐Silberstein, H. Fleury, M. Levrero, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.

M. Ciotti, G. Tisone, I. Lenci, 2011, Journal of hepatology.

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection

Domenico Di Carlo, S. Grelli, M. Andreoni, 2020, Emerging microbes & infections.

Understanding HIV Compartments and Reservoirs

F. Ceccherini‐Silberstein, A. Antinori, S. Aquaro, 2014, Current HIV/AIDS Reports.

Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

L. Milanesi, F. Ceccherini‐Silberstein, E. Teti, 2021, Viruses.

Successful ongoing retreatment with glecaprevir/pibrentasvir+sofosbuvir+ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.

F. Ceccherini‐Silberstein, I. Lenci, M. Milana, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets

F. Ceccherini‐Silberstein, H. Fleury, M. Andreoni, 2018, Viruses.

HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort

E. Teti, M. Andreoni, L. Coppola, 2021, Microorganisms.

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort

E. Teti, M. Andreoni, S. Parisi, 2023, Viruses.

HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy

E. Teti, M. Andreoni, V. Svicher, 2019, Scientific Reports.

A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy.

C. Perno, R. Mariani, M. Dalessandro, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression

Y. Louzoun, C. Perno, M. Andreoni, 2014 .

Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance

C. Perno, M. Andreoni, A. Bertoli, 2011, Infection.

The Role of HIV Infection in Neurologic Injury

S. Aquaro, C. Perno, V. Svicher, 2017, Brain sciences.

Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers

E. Teti, M. Andreoni, G. Sotgiu, 2021, Scientific Reports.

High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations

F. Ceccherini‐Silberstein, F. Gago, A. Antinori, 2005, Journal of Virology.

Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors

Valentina Svicher, Francesca Ceccherini-Silberstein, F. Ceccherini‐Silberstein, 2005, Antimicrobial Agents and Chemotherapy.

Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage

F. Ceccherini‐Silberstein, S. Aquaro, C. Perno, 2019, Medicina.

Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control

F. Ceccherini‐Silberstein, S. Alcaro, G. Costa, 2020, The Journal of antimicrobial chemotherapy.

HHV-8 genetic diversification and its impact on severe clinical presentation of associated diseases.

F. Ceccherini‐Silberstein, V. Svicher, M. Bellocchi, 2020, The Journal of infectious diseases.

Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice

F. Ceccherini‐Silberstein, A. Antinori, M. Zazzi, 2019, Virus Genes.

Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile

F. Ceccherini‐Silberstein, S. Alcaro, G. Costa, 2022, Microbiology spectrum.

Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2018, Scientific Reports.

Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia

F. Ceccherini‐Silberstein, A. Antinori, C. Mussini, 2015, Journal of Clinical Microbiology.

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.

Jeroen Aerssens, Valentina Svicher, Loredana Sarmati, 2011, Antiviral research.

Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3 signatures in the regulation of Co-Receptor usage

F. Ceccherini‐Silberstein, C. Perno, V. Svicher, 2011, Retrovirology.

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens

F. Ceccherini‐Silberstein, P. Narciso, K. Van Laethem, 2010, Journal of acquired immune deficiency syndromes.

Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.

Stefano Bonora, Valentina Svicher, P. Narciso, 2006, The Journal of antimicrobial chemotherapy.

Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy

M. Andreoni, C. Perno, A. Bertoli, 2016, AIDS.

Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.

F. Ceccherini‐Silberstein, O. Turriziani, M. Andreoni, 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors

Thomas Lengauer, Stefano Alcaro, Jan Balzarini, 2007, Journal of Virology.

Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors

Thomas Lengauer, A. d’Arminio Monforte, F. Ceccherini‐Silberstein, 2006, Journal of Virology.

Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking

Thomas Lengauer, Niko Beerenwinkel, Hauke Walter, 2005, PKDD.

Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein Rev

A. Laganà, F. Ceccherini‐Silberstein, A. Ferro, 2009, Antimicrobial Agents and Chemotherapy.

SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021

R. Shafer, F. Ceccherini‐Silberstein, S. Alcaro, 2021, Microbiology spectrum.

Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.

F. Ceccherini‐Silberstein, J. Balzarini, S. Aquaro, 2005, The Journal of antimicrobial chemotherapy.

The degree of HIV-1 amino acid variability is strictly related to different disease progression rates

C. Mussini, A. Cossarizza, S. Aquaro, 2018, Virus Genes.

The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2016, Journal of global antimicrobial resistance.

Detection of high levels of Survivin–immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis

G. Rasi, P. Pontisso, S. Bernardini, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis

V. Svicher, L. Sarmati, V. Malagnino, 2023, Frontiers in Oncology.

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients

F. Ceccherini‐Silberstein, E. Teti, M. Andreoni, 2022, Biomedicines.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

F. Ceccherini‐Silberstein, E. Nicastri, C. Perno, 2015, The Journal of antimicrobial chemotherapy.

HIV-2 A-subtype gp125C2-V3-C3 mutations and their association with CCR5 and CXCR4 tropism

F. Ceccherini‐Silberstein, C. Perno, V. Svicher, 2011, Archives of Virology.

Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage

Chang Liu, Stefano Alcaro, Anna Artese, 2013, Bioinform..

Highlights on HIV eradication in 2013.

A. Lazzarin, G. Marchetti, A. Monforte, 2014, AIDS.

Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach

F. Ceccherini‐Silberstein, E. Tramontano, S. Alcaro, 2023, J. Chem. Inf. Model..

SARS-CoV-2 Mutations and Variants May Muddle the Sensitivity of COVID-19 Diagnostic Assays

F. Ceccherini‐Silberstein, V. Svicher, L. Carioti, 2022, Microorganisms.

Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.

F. Ceccherini‐Silberstein, S. Aquaro, C. Perno, 2020, The Journal of antimicrobial chemotherapy.

Supervised and Unsupervised Approaches for Analyzing Covariation and Phenotypic Impact of HIV Drug Resistance Mutations

Thomas Lengauer, Niko Beerenwinkel, Tobias Sing, 2005, LWA.

The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature.

V. Calvez, F. Ceccherini‐Silberstein, C. Perno, 2014, The Journal of infection.

HIV-1-associated dementia during HAART therapy.

S. Aquaro, C. Perno, V. Svicher, 2008, Recent patents on CNS drug discovery.

Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2006, The new microbiologica.

Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.

F. Ceccherini‐Silberstein, C. Perno, V. Svicher, 2012, Virus research.

Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group

A. d’Arminio Monforte, F. Baldanti, F. Ceccherini‐Silberstein, 2013, Infection.

'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.

F. Ceccherini‐Silberstein, P. Narciso, M. Capobianchi, 2011, The Journal of antimicrobial chemotherapy.

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

F. Ceccherini‐Silberstein, P. Narciso, C. Perno, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The lowest X 4 Geno 2 Pheno false-positive rate is associated with greater CD 4 depletion in HIV-1 infected patients

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2012 .

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Subtype analysis and mutations to antiviral drugs in HIV‐1‐infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme

L. Palombi, C. Perno, M. Marazzi, 2005, Journal of medical virology.

Molecular Dynamics and Free Energy Studies on the Wild-Type and Mutated HIV-1 Protease Complexed with Four Approved Drugs: Mechanism of Binding and Drug Resistance

Stefano Alcaro, Anna Artese, Tobias Sing, 2009, J. Chem. Inf. Model..

Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2018, Scientific Reports.

Description of the L76V Resistance Protease Mutation in HIV-1 B and “Non-B” Subtypes

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2013, PloS one.

Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.

F. Ceccherini‐Silberstein, C. Perno, S. Alcaro, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

Domenico Di Carlo, F. Ceccherini‐Silberstein, M. Andreoni, 2015, The Journal of antimicrobial chemotherapy.

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.

M. Ciotti, G. Tisone, I. Lenci, 2011, Journal of hepatology.

GS-17-The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative disease: Implications for the treatment and management of CHB

C. Perno, A. Nuccitelli, V. Svicher, 2019, Journal of Hepatology.

Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort

C. Mussini, A. Tavelli, S. Lo Caputo, 2023, Liver international : official journal of the International Association for the Study of the Liver.

Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients

F. Ceccherini‐Silberstein, Federica Moraca, B. Catalanotti, 2023, Pharmaceuticals.

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.

F. Ceccherini‐Silberstein, S. Aquaro, C. Perno, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.